RT Journal Article
T1 Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients.
A1 Caballero-Marcos, Aranzazu
A1 Salcedo, Magdalena
A1 Alonso-Fernandez, Roberto
A1 Rodriguez-Peralvarez, Manuel
A1 Olmedo, Maria
A1 Graus Morales, Javier
A1 Cuervas-Mons, Valentin
A1 Cachero, Alba
A1 Loinaz-Segurola, Carmelo
A1 Iñarrairaegui, Mercedes
A1 Castells, Lluis
A1 Pascual, Sonia
A1 Vinaixa-Aunes, Carmen
A1 Gonzalez-Grande, Rocio
A1 Otero, Alejandra
A1 Tome, Santiago
A1 Tejedor-Tejada, Javier
A1 Alamo-Martinez, Jose Maria
A1 Gonzalez-Dieguez, Luisa
A1 Nogueras-Lopez, Flor
A1 Blanco-Fernandez, Gerardo
A1 Muñoz-Bartolo, Gema
A1 Bustamante, Francisco Javier
A1 Fabrega, Emilio
A1 Romero-Cristobal, Mario
A1 Martin-Mateos, Rosa
A1 Del Rio-Izquierdo, Julia
A1 Arias-Milla, Ana
A1 Calatayud, Laura
A1 Marcacuzco-Quinto, Alberto A
A1 Fernandez-Alonso, Victor
A1 Gomez-Gavara, Concepcion
A1 Colmenero, Jordi
A1 Muñoz, Patricia
A1 Pons, Jose A
K1 Clinical research/practice
K1 Immune regulation
K1 Immunosuppressant
K1 Immunosuppression/immune modulation
K1 Infection and infectious agents-viral
K1 Infectious disease
K1 Liver transplantation/hepatology
AB The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95%CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline.
PB Elsevier
YR 2021
FD 2021-03-29
LK http://hdl.handle.net/10668/17554
UL http://hdl.handle.net/10668/17554
LA en
NO Caballero-Marcos A, Salcedo M, Alonso-Fernández R, Rodríguez-Perálvarez M, Olmedo M, Graus Morales J, et al. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. Am J Transplant. 2021 Aug;21(8):2876-2884
DS RISalud
RD Apr 5, 2025